Marta Sonia González

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero et al. · Blood · 2019 · 62 citations

Medicine, Hematology, Oncology +11

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

Camila Guerrero, Noemí Puig, María‐Teresa Cedena et al. · Clinical Cancer Research · 2022 · 36 citations

Medicine, Clinical Sciences, Oncology +13

Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature

Ramón Lecumberri, Isabel Krsnik, Elham Askari et al. · Amyloid · 2020 · 34 citations

Medicine, Hematology, Pharmacotherapy +14

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero et al. · Journal of Clinical Oncology · 2024 · 31 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

Noemí Puig, Laura Rosiñol, Esther González et al. · Blood Cancer Journal · 2021 · 29 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14